The therapy will be used for non-small cell lung cancer. Credit: mi_viri/Shutterstock. Apollomics and LaunXP have signed an agreement to develop and commercialise the former’s c-Met inhibitor vebreltinib combined with an epidermal growth factor receptor inhibitor (EGFRi) for treating non-small cell lung cancer (NSCLC) in Asian territories excluding Macau, mainland China and Hong Kong. LaunXP will pay Apollomics $10m upfront within 60 days of the agreement date. Apollomics is also qualified for p

The candidate is under development for treating ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, and bloodstream infections. Credit: CrizzyStudio / Shutterstock. Biopharmaceutical company BioVersys has announced the grant of key patent claims in China for BV100, the intravenous formulation of rifabutin. The technology is being developed to combat resistant hospital infections caused by the Acinetobacter baumannii-calcoaceticus complex, including carbapenem-resist

WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. “We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio,” said Aoife Brennan, President and CEO of Climb Bio. “Kim and Bo each brin

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 1, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), today announced the closing of its previously announced private placement. Jaguar's president and chief executive officer Lisa Conte , as well as other members of the Company's board of directors and other C-suite and senior executives of Jaguar along with selected institutional and accredited investors (each, an "Investor") entered into securities purchase agreements in c

TOKYO and CAMBRIDGE, Mass., April 1, 2025 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as a treatment for early AD (mild cognitive impairment and mild dementia due to Alzheimer’s disease (AD)) by the European Commission (EC). The final pro

REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations will be featured at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, held from April 25 – 30, 2025. The first clinical data in non-small cell lung cancer from the Phase 1 study of zoldonrasib, a RAS(ON) G12D-sele

Pfizer’s respiratory syncytial virus (RSV) vaccine has been approved by the European Commission (EC) to prevent RSV-associated lower respiratory tract disease (LRTD) in individuals aged 18 to 59 years. The expanded indication makes Abrysvo the first and only RSV vaccine approved in the EU for non-pregnant adults in this age population. RSV is a common contagious virus characterised by several mild, cold-like symptoms. Although most people recover within a week or two, the virus can cause severe

NEEDHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the publication of a manuscript reporting the results of a phase 1b clinical trial exploring safety and tolerability of the combination of CAN-2409 plus prodrug (valacyclovir) and nivolumab, in addition to standard of care (neurosurg

With reference to Gubra’s A/S (CPSE: GUBRA) announcement on March 28, 2025 regarding the satisfaction of the regulatory condition for a license agreement to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity, all closing conditions of the license agreement have today been satisfied and the license agreement has become effective. Contacts at GubraMedia: Sofia Pitt Boserup, sbo@gubra.dk, +45 4188 9586Investors: Kristian Borbos, kbo@gubra.dk, +45 30

iStock, avgust01 AIRNA’s lead candidate AIR-001 works by correcting the most common pathologic mutation driving the rare disease alpha-1 antitrypsin deficiency. RNA editing startup AIRNA closed its series B financing round on Tuesday, counting $155 million in earnings that will allow it to perform clinical trials on its lead molecule. The Cambridge, MA and Tübingen, Germany–based company is developing an investigational RNA editor called AIR-001 to treat alpha-1 antitrypsin deficiency (AATD),